{"artifact_id":"analysis-sda-2026-04-01-gap-008","artifact_type":"analysis","title":"Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.","quality_score":0.8,"is_latest":1,"version_number":6,"version_count":1,"debate_count":0,"supports_count":0,"contradicts_count":0,"neutral_count":0,"incoming_by_type":{"derives_from":112,"related":41,"mentions":1222},"total_incoming":1375,"outgoing_by_type":{"related":1028,"produces":1,"mentions":1},"total_outgoing":1030,"quality_trajectory":[{"score":0.8,"at":"2026-05-16T14:51:34.657673-07:00"},{"score":0.8,"at":"2026-05-16T08:03:22.955306-07:00"},{"score":0.8,"at":"2026-04-28T20:23:41.682745-07:00"},{"score":0.8,"at":"2026-04-28T20:23:41.682745-07:00"},{"score":0.8,"at":"2026-04-28T03:48:49.857966-07:00"}],"evidence_balance":0.0,"evidence_certainty":1.0,"total_evidence_items":2405,"is_well_supported":false,"is_controversial":false,"is_foundational":true}